Danaher to Launch AI-Powered Autonomous Research Lab

Pharmaceutical research labs are increasingly blurring the line between the physical and virtual worlds. The traditional image of scientists in white coats working at laboratory benches is giving way to increasingly connected, automated research environments straddling the physical and virtual realms.

Developing these hybrid labs is now emerging as a key priority among some of the pharmaceutical sector’s biggest players. 

Combining AI, robotics and laboratory automation, these closed-loop systems can independently plan, execute and analyse experiments with minimal human intervention, creating a continuous cycle between digital design and physical experimentation.

Danaher offers the latest example of this trend, as the firm announced plans to launch its “first AI-powered autonomous lab.”

Expected to become operational in early 2027, the lab will fuse AI, robotics and various Danaher technologies into a single workflow to help researchers rapidly develop custom antibodies and molecular tools.

Danaher CEO Julie Sawyer Montgomery says the lab will help “researchers move from an idea to tested and validated affinity reagents up to 8x faster while maintaining scientific rigour.

“This is the full power of Danaher in action, bringing together our science, technology and culture of continuous improvement to accelerate the journey from discovery to impact.”

Unifying Danaher’s technological capabilities

Based at Danaher company Abcam, the lab will use AI to design affinity reagents, including antibodies, before automatically building and testing each candidate. 

The results are then fed back into the AI model, allowing it to refine subsequent designs and create a continuous design-make-test-learn cycle.

The lab connects technologies from across Danaher’s portfolio, bringing together capabilities from Beckman Coulter Life Sciences, Cytiva, Genedata, Integrated DNA Technologies and Molecular Devices within a single workflow. Robotic automation and device orchestration, meanwhile, have been developed in collaboration with Automata.

By continuously feeding experimental data back into the design process, the lab aims to compress research cycles while maintaining the rigour of repeated testing and validation.

Luciano Lucas, Vice President and Enterprise Head of Autonomous and Intelligent Labs at Danaher, believes the proposed lab will redefine the future of scientific discovery.

On LinkedIn, he writes: “We are…building a broader foundation for the future of science: a new generation of intelligent scientific devices designed to generate AI-ready data, integrate seamlessly into customer-defined workflows, be easily controlled programmatically…incorporate expert-level agentic capabilities, simplify operation, improve data quality and help researchers gain deeper insights. 

“These capabilities can benefit scientists whether they work in manual, semi-automated, or fully autonomous environments.”

Autonomous labs on the rise

Danaher’s announcement comes as pharmaceutical and biotech companies increasingly explore how AI, automation and advanced data infrastructure could reshape the laboratory itself.

Roche has said it is developing autonomous, AI-driven laboratories to accelerate R&D and drug discovery, alongside a wider push towards “AI independence” across its research operations. 

The company is targeting up to 20 new molecular entities by 2030, highlighting its growing ambition to connect computational intelligence with physical experimentation.

The shift is also visible among AI-native drug discovery companies. Recursion Pharmaceuticals, for example, operates automated laboratories as part of Recursion OS, connecting physical experimentation with machine learning in a continuous feedback loop. 

Its platform can run up to two million experiments a week, with experimental data feeding back into its models to inform subsequent discovery.

Meanwhile, Isomorphic Labs has developed an AI-first approach to drug discovery, using AI models and large-scale computational experiments alongside expertise spanning machine learning, chemistry and biology. 

Insilico Medicine has taken a similarly integrated approach, connecting its AI drug discovery platform with an automated laboratory capable of carrying out experiments and feeding the resulting data back into its models. 

Danaher - key partners

Automata

CEO: Mostafa ElSayed  | HQ: London, UK

Automata is a laboratory automation company developing AI-ready infrastructure for life sciences research. Its LINQ platform connects laboratory instruments, robotics and software to automate complex experimental workflows. Danaher invested in Automata’s US$45m Series C in January 2026, while Automata’s technology is being used for device orchestration and robotic automation in Danaher’s upcoming autonomous lab.

AstraZeneca

CEO: Pascal Soriot | HQ: Cambridge, UK

AstraZeneca is a global biopharmaceutical company focused on discovering, developing and commercialising medicines across areas including oncology, cardiovascular, renal and metabolic diseases, respiratory and immunology. Danaher and AstraZeneca established a partnership in 2025 to develop and commercialise novel diagnostic tools, including AI-powered diagnostics, designed to help identify patients most likely to benefit from precision medicines. 

Innovaccer

CEO: Abhinav Shashank | HQ: San Francisco, California

Innovaccer develops AI-powered healthcare technology designed to connect data, applications and workflows across healthcare organisations. Danaher Ventures has described Innovaccer as a strategic AI-centric partner focused on patient health, with the relationship extending beyond investment into potential co-development, co-marketing and co-distribution opportunities. The partnership reflects Danaher’s broader strategy of combining external digital innovation with its life sciences and healthcare portfolio.